## **PRODUCT** INFORMATION



Vimentin Monoclonal Antibody (Clone 12E4)

Item No. 20197

#### **Overview and Properties**

| Contents:<br>Synonym:<br>Immunogen: | This vial contains 100 μg of protein G-purified monoclonal antibody.<br>VIM<br>Recombinant human vimentin   |
|-------------------------------------|---|
| Cross Reactivity:                   | (+) Vimentin, citrullinated vimentin  |
| Species Reactivity:                 | : (+) Human; other species not tested   |
| Uniprot No.:                        | P08670  |
| Form:                               | Liquid  |
| Storage:                            | -20°C (as supplied)   |
| Stability:                          | ≥3 years  |
| Storage Buffer:                     | PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide   |
| Clone:                              | 12E4  |
| Host:                               | Mouse   |
| Isotype:                            | lgG2a   |
| Applications:                       | ELISA, Immunoprecipitation (IP), and Western blot (WB); the recommended starting dilution is 1:1,000 for ELISA and WB, and 5 $\mu$ g per IP test (20 $\mu$ l resin). Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically. |

#### Image



Lane 1: Recombinant Vimentin (25 ng) Lane 2: HEK293 Cell Lysates (10 µg) Lane 3: HeLa Cell Lysates (10 µg) Lane 4: Recombinant Vimentin (25 ng) + 10 µg/ml immunizing protein Lane 5: HEK293 Cell Lysates  $(10 \ \mu g) + 10 \ \mu g/ml$  immunizing protein Lane 6: HeLa Cell Lysates  $(10 \ \mu g) + 10 \ \mu g/ml$  immunizing protein

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/21/2023

### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

# **PRODUCT** INFORMATION



#### Description

Vimentin is a cytoskeleton intermediate filament protein.<sup>1</sup> It is composed of monomers that each contain a central α-helix rod domain, which facilitates formation of a coiled-coil dimer required for vimentin filament assembly, as well as N-terminal head and C-terminal tail domains.<sup>1,2</sup> It is expressed in mesenchymal stem cells and cells of mesenchymal origin, including leukocytes, endothelial cells, and smooth muscle cells.<sup>3</sup> Vimentin is attached to nuclei, endoplasmic reticulum, and mitochondria, and has a role in positioning organelles in the cytosol.<sup>2</sup> It regulates glial morphology, facilitates motility and directional migration of fibroblasts, and is critical to mechanotransduction of shear stress and maintenance of vascular endothelial integrity.<sup>1</sup> Vimentin controls transport of LDL-derived cholesterol from lysosomes to esterification sites.<sup>4</sup> It is an aggresome component, forming a cage-like structure around aggregated, undegraded proteins at the microtubule organizing center.<sup>5</sup> Vimentin is subject to citrullinated vimentin has been shown to have a role in the production of anti-citrullinated protein antibodies (ACPAs).<sup>6,7</sup> ACPAs against citrullinated proteins, such as vimentin, are considered to be highly specific markers for rheumatoid arthritis and other autoimmune diseases.<sup>6</sup> Cayman's Vimentin Monoclonal Antibody (Clone 12E4) can be used for ELISA, immunoprecipitation (IP), and Western blot (WB) applications. The antibody recognizes vimentin at approximately 54 kDa from human samples.

#### References

- Eriksson, J.E., Dechat, T., Grin, B., et al. Introducing intermediate filaments: From discovery to disease. J. Clin. Invest. 119(7), 1763-1771 (2009).
- 2. Chang, L., Shav-Tal, Y., Trcek, T., et al. Assembling an intermediate filament network by dynamic cotranslation. J. Cell. Biol. 172(5), 747-758 (2006).
- Franke, W.W., Grund, C., Kuhn, C., *et al.* Formation of cytoskeletal elements during mouse embryogenesis. III. Primary mesenchymal cells and the first appearance of vimentin filaments. *Differentiation* 23(1), 43-59 (1982).
- Sarria, A.J., Panini, S.R., and Evans, R.M. A functional role for vimentin intermediate filaments in the metabolism of lipoprotein-derived cholesterol in human SW-13 cells. J. Biol. Chem. 267(27), 19455-19463 (1992).
- Johnston, J.A., Ward, C.L., and Kopito, R.R. Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 143(7), 1883-1898 (1998).
- Soós, L., Szekanecz, Z., Szabó, Z., et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J. Rheumatol. 34(8), 1658-1663 (2007).
- 7. Asaga, H., Yamada, M., and Senshu, T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. *Biochem. Bioph. Res. Commun.* **243(3)**, 641-646 (1998).

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM